Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application baricitinib tablets, 1mg and 2mg. Aurobindo Pharma’s, baricitinib tablets are an AB-rated generic equivalent to the reference listed drug (RLD),Olumiant Tablets, manufactured by Eli Lilly and Company.
Baricitinib tablets are indicated for the treatment of Rheumatoid Arthritis.
Baricitinib tablets has an estimated market size of US $367 Million for the twelve months ending May 2024, as per IQVIA.
